Skip to nav Skip to content
  • Cancer Type: Malignant Hematology
  • Study Type: Treatment
  • NCT#: NCT03150693
  • Phase: Phase III
Learn More
  • Overview

    Study Title:

    A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzomab Ozogamicin (a conjugated anti-CD22 monoclonal antibody) to Frontline Therapy in Young Adults (ages 18-39 years) with Newly Diagnosed Precusor B-cell ALL

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

Clinical Trial Search